Furthermore, our previous work demonstrates that activation of IGF1R in HNSCC can result in resistance to targeted EGFR inhibitors7 and highlights the need for improved mechanistic insight to combat therapeutic resistance. Here, IGF1R is linked to head and neck squamous cell carcinoma.